louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04949906: Study on Yangxue Nao Granules Reducing the Risk of Stroke
Official title: A Real World Study of Yangxuenao Granules Reducing Bleeding Risk in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Infarction
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-02
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A cohort of patients admitted to the Department of Emergency Neurology at Peking University Third Hospital on January 1, 2017 and admitted on September 30, 2019, who were diagnosed with acute ischemic stroke and underwent intravenous thrombolysis.

Brief summary: Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the real world

Detailed description: Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the real world Study Design. This study was a single center real world study. Through the review data, this study included in January 1, 2017 to September 30, 2019, see a doctor at Peking University third hospital neurology, emergency diagnosis of acute ischemic stroke, and venous thrombolysis in patients with a queue, on the basis of whether the application have serum brain particles are divided into a group and the control group, serum application parameters and nonparametric comparison, K-M curve and Cox regression model were used to evaluate the effectiveness of Yangxuenao granules in reducing bleeding conversion after intravenous thrombolysis by comparing the number of microbleeding, stroke severity score and modified Rankin score after 3 months follow-up with the weighted craniocerebral magnetic sensitivity imaging sequence reexamined within 48 hours.

Eligibility criteria: Inclusion Criteria:

* A cohort of patients admitted to the Department of Emergency Neurology at Peking University Third Hospital on January 1, 2017 and admitted on September 30, 2019, who were diagnosed with acute ischemic stroke and underwent intravenous thrombolysis.

Exclusion Criteria:

* Patients who underwent intravenous thrombolysis but were confirmed to be apoplexy
* like by imaging and other clinical examinations; Incomplete craniocerebral MRI examination;
* Bridging endovascular therapy;
* The previous application of Yangxuenao granules or other drugs with similar effects;

Primary outcomes:
measure: Microhemorrhage (CMB) of T2* sequence in MRI after thrombolysis
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Yniversity Third Hospital
Study officials:
References:
Clinical trial NCT04145206: Ankle Instability in Flamenco Dancers
Official title: Ankle Instability in Flamenco Dancers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ankle Disease
Dance
Keywords: ankle
dance
Lead sponsor: University of Seville
Sponsor class: OTHER
First posted: 2019-10-30
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study has involved a population of 26 healthy subjects divided into two groups of 13 each one

Brief summary: The injuries in the dancers are usually associated with different factors such as the characteristics of the footwear, height of the heel and physical requirements, the articulation of the ankle being the most susceptible when the loads are not adequately dealt. The main objective is to evaluate in a sample of subjects if there is a difference in the stability of the ankle, as a consequence of previous sprains, between flamenco dancers and dancers and a dance-free control group.

Detailed description: An observational study. This study has involved a population of 26 subjects divided into two groups of 13 each is studied (40,15 ± 4,675 años); the experimental group is characterized by the practice of flamenco dance

Eligibility criteria: Inclusion Criteria:

Flamenco dancers

-

Exclusion Criteria:

* no

Primary outcomes:
measure: Ankle drawer test
timeFrame: A day, the inclusion day in the study
Secondary outcomes:
Other outcomes:
Locations:
city: Sevilla
country: Spain
facility: Aurora Castro Mendez
Study officials:
References:
Clinical trial NCT01503606: Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane
Official title: Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane, Phase III Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Preterm Premature Rupture of Membrane
Keywords: preterm premature rupture of membrane
antibiotics
duration
cefazolin
clarithromycin
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2012-01-04
Enrollment: 151
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the neonatal outcome and infant neurologic outcome whose mother were treated with cefazolin plus clarithromycin for one week or until delivery after preterm premature rupture of membrane.


Eligibility criteria: Inclusion Criteria:

* preterm premature rupture of membrane(PPROM), PA 22+0\~34+0wks
* ROM \<72 hrs before randomization
* cervical dilatation \<3cm
* uterine contraction less than 4 times per 1 hr

Exclusion Criteria:

* Major fetal malformation
* Rupture of the membrane \>72hrs before randomization
* Vaginal bleeding
* IIOC (incompetent internal os of cervix)
* Placenta previa
* Gestational diabetes or overt diabetes
* Hypertensive disorders in pregnancy
* Liver cirrhosis
* Acute renal failure

Primary outcomes:
measure: Neonatal composite morbidity
timeFrame: Participants will be followed for duration of hospital day after delivery, an expected average of 8 weeks
Secondary outcomes:
measure: infantile neurologic outcome
timeFrame: at 6 months and 1 year of corrected age
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical center, Sungkyunkwan University School of Medicine
Study officials:
affiliation: Samsung Medical Center, Sungkyunkwan University School of Medicine
name: Soo-young Oh, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04445506: Short Term Corticosteroids in SARS-CoV2 Patients
Official title: The Effect of the Short-term Use of Systemic Corticosteroids in COVID-19 Patients in Regard to Hospital Length of Stay, Morbidly and/or Mortality.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Corticosteroids
Covid19
SARS-CoV 2
Steroids
Dexamethasone
Lead sponsor: The Miriam Hospital
Sponsor class: OTHER
First posted: 2020-06-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients aged 18 years and older with positive SARS-CoV2 test with CRP greater than 50 mg/L and having greater than 2L Oxygen requirement

Brief summary: The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.


Eligibility criteria: Inclusion Criteria:

1. Moderate disease with at least a 30% increase in CRP within 36 hours of admission, and with increasing oxygen requirements.
2. All patients with severe disease with evidence of escalating oxygen requirements
3. The presence of secondary bacterial infections as a probable cause of increasing CRP levels was excluded in all selected patients.
4. Pulmonary embolism and /or cardiac dysfunction were excluded as probable causes of worsening hypoxia in all selected patients.

Exclusion Criteria:

1. All patients on other treatment modalities- Remdesivir and/or Convalescent plasma who showed evidence of clinical improvement as per decrease in CRP levels and/or oxygen requirements were excluded.
2. Patient with associated COPD exacerbation who would benefit from the use of steroids.
3. Patients with Diabetic ketoacidosis, hyperglycemic hyperosmolar state, active concurrent bacterial infections.
4. Patients with history of steroid-induced mania and/or psychosis.

Primary outcomes:
measure: Effect on transfers to ICU and escalation of care needing mechanical ventilation
timeFrame: 2 months
Secondary outcomes:
measure: Effect on length of stay
timeFrame: 2 months
measure: Change in CRP levels
timeFrame: 2 months
Other outcomes:
Locations:
city: Providence
country: United States
facility: The Miriam Hospital
state: Rhode Island
Study officials:
affiliation: The Miriam Hospital
name: Kwame Dapaah-Afriyie, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00325806: Ramipril - Hypertension
Official title: Prevention of Hypertension in Patients With High-Normal Blood Pressure With the Angiotensin-Converting-Enzyme-Inhibitor Ramipril - a Randomised Prevention Trial of the German Hypertension League.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2006-05-15
Enrollment: 1008
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary objective:

Mean values of systolic and diastolic office blood pressure

Secondary objectives:

Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation


Eligibility criteria: Inclusion Criteria:

* no previous antihypertensive therapy
* high-normal blood pressure according to the JNC-VI definition (systolic 130 - 139 and/or diastolic 85 - 89 mmHg)

Exclusion Criteria:

* antihypertensive therapy
* blood pressure greater 140/90 mmHg or ABPM greater 135/85 mmHg

Primary outcomes:
measure: Mean systolic and diastolic 24-hour blood pressure in ABPM
Secondary outcomes:
measure: Overall mortality and total number of cardiovascular and cerebro-vascular events
measure: Changes in mean blood pressure readings over time
measure: Reasons for admissions to hospital/-stays
measure: Occurrence of pathological fasting glucose levels in serum/pathological HbA1c levels.
Other outcomes:
Locations:
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References:
citation: Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M, Middeke M, Motz W, Lubcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008 Jul;26(7):1487-96. doi: 10.1097/HJH.0b013e3282ff8864.
Clinical trial NCT02492906: Neuroimaging of Patients With Severe Knee Osteoarthrosis - Evaluation of Cerebral Volumetry
Official title: Neuroimaging of Patients With Severe Knee Osteoarthrosis - Evaluation of Cerebral Volumetry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoarthritis, Knee
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2015-07-09
Enrollment: 56
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy patients and patients with primary severe knee osteoarthrosis and with chronic knee pain were included.

Brief summary: Due to scarce published articles about this subject, the researchers aim to study the volume measurements of the brain cortex of patients with primary severe knee osteoarthrosis and those with chronic knee pain compared to healthy and non-symptomatic volunteers, correlating the neuroimaging of cerebral volumetry with pain intensity, pain duration, knee function and pressure pain threshold.

Detailed description: The protocol was designed to include 31 patients in each observational arm, either patients with severe knee osteoarthrosis and chronic knee pain or healthy and non-symptomatic volunteers.

The researchers performed anamnesis to collect clinical and demographic information, the intensity of pain was assessed by the self-rated Visual Analogue Scale (VAS), the pressure pain threshold was evaluated with an algometer, the knee function was assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale and the images were collected with the use of the Magnetic Resonance.

Covariates, such as age, gender, Body Mass Index (BMI) and comorbidities as diabetes, cardiac diseases, pulmonary diseases, endocrine diseases and the practice of physical activities were also collected.

Eligibility criteria: Inclusion Criteria:

* Age above 60 years old;
* Both genders;
* Clinical diagnosis of knee osteoarthrosis;
* Self-rated VAS moderate to severe (VAS \> 4);
* Pain duration longer than 3 months prior to the evaluation;
* Signed Informed Consent;
* Light physical activity practice or sedentary (healthy volunteers only).

Exclusion Criteria:

* Presence of psychiatric disorders;
* Presence of fibromyalgia;
* Presence of rheumatologic diseases;
* Presence of previous knee surgery;
* Presence of clinical symptoms (healthy volunteers only);
* Presence of knee pain on the previous 6 months (healthy volunteers only);
* History of neoplasia.

Primary outcomes:
measure: Cerebral Volumetry Comparison
timeFrame: Baseline at time of evaluation.
Secondary outcomes:
measure: VAS Comparison
timeFrame: Baseline at time of evaluation.
measure: Pressure Pain Threshold Comparison
timeFrame: Baseline at time of evaluation.
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Instituto de Medicina Fisica e Reabilitacao HCFMUSP
Study officials:
affiliation: Instituto de Medicina Física e Reabilitação HCFMUSP
name: Marta Imamura, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05544799: Case Studies of Patients Who Had Experienced Near Death Experience
Official title: Case Studies of Patients Who Had Experienced Near Death Experience
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Near Death Experience
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2022-09-16
Enrollment: 200
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with hematologic cancers who are in admission.

Brief summary: An prospective observational study to interview patients who had near death experiences among those who had received intensive care unit intervention during admission in hematology ward.


Eligibility criteria: Inclusion Criteria:

* Adult patients (≥19yrs) who are in admission in the Hematology ward of Seoul National University Hospital, and one of the following conditions.

  1. recovered after cardiopulomary resuscitation
  2. recovered after mechanical ventilator
  3. recovered after ICU care
  4. recovered after emergent operation
  5. recovered after Shock, coma, altered mentality
  6. Other medical conditions approaching death

Exclusion Criteria:

1. Those who do not agree to participate this study
2. Those who can not be interviewed due to insufficient recovery from critical medical problems

Primary outcomes:
measure: Incidence of near death experience (NDE)
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Department of Internal Medicine, Seoul National University Hospital
name: Dong-Yeop Shin, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01524406: Safety Study of HPP593 in Subjects During and After Limb Immobilization
Official title: A Randomized, Double-blind, Placebo Controlled, Phase I Study to Evaluate the Safety and Tolerability of 28 Day Treatment With HPP593 Capsules in Healthy Volunteers During and After Limb Immobilization
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Muscle Atrophy
Hypodynamia
Keywords: Muscle Atrophy
Lead sponsor: High Point Pharmaceuticals, LLC.
Sponsor class: INDUSTRY
First posted: 2012-02-02
Enrollment: 24
Sex: MALE
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This is a safety and tolerability study investigating the effect of HPP593 in healthy volunteers during and after limb immobilization.


Eligibility criteria: Inclusion Criteria:

* Non-smoking.
* Subjects must be in good health, as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical test results.
* Not restricted to a wheel-chair or confined to a bed.
* Weight ≥ 50.0 kg.
* BMI between 18 and 27.5 kg/m2, inclusive, at the time of screening.

Exclusion Criteria:

* Any of the following abnormalities at Screening Visit and Baseline:

  * Fasting glucose \> 110 mg/dL (Screening visit only).
  * Serum creatinine \> 1.5 mg/dL. If serum creatinine is \>1.5 mg/dL and creatinine clearance is \>60 mL/min, the subject need not be excluded
  * Troponin I level above the upper limit of normal (ULN)
  * Liver function tests (LFTs) \> 1.5x ULN
* Evidence of significant organ system dysfunction (e.g. diabetes, cardiovascular disease, cirrhosis, hypogonadism, hypo- or hyperthyroidism; hypertension)
* Any fluctuations in weight (no more than ± 2% of body weight) by subject self report in the 3 months prior to the Screening Visit.
* Has received HPP593 in a previous clinical trial.
* Smoking within 6 month prior to Day -1.
* Michigan Alcohol Screening Test score greater than 2.

Primary outcomes:
measure: Safety Evaluation
timeFrame: Baseline to Day 42
Secondary outcomes:
measure: Change in Muscle Strength
timeFrame: Day 1 to Day 42
measure: Changes on Muscle Related Biomarkers
timeFrame: Day 1 to Day 29
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Washington University School of Medicine Division of Geriatrics and Nutritional Studies
state: Missouri
Study officials:
affiliation: High Point Pharmaceuticals, LLC.
name: Shulin Wang, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04654806: Assessment of Left Ventricular Diastolic Function in Patients With Atrial Fibrillation
Official title: Assessment of Left Ventricular Diastolic Function in Patients With Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2020-12-04
Enrollment: 200
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who scheduled to perform radiofrequency catheter ablation for atrial fibrillation

Brief summary: This study is a single-center, prospective cohort study to investigate non-invasive method to assess left ventricular diastolic function using echocardiography. Patients with AF who are referred radiofrequency catheter ablation (RFA) will be included prospectively. Transthoracic echocardiography will be performed during, immediately before RFA and with no cardiovascular medication taken between the exams so that the loading conditions during catheterization and echocardiography are as similar as possible. We will validate previously proposed echocardiographic parameters and creat an algorithm to identify the relationship between echocardiographic parameters of diastolic function and invasively measured LA pressure in patients with atrial fibrillation.


Eligibility criteria: Inclusion Criteria:

* Adult ≥ 19 year-old
* Patients who scheduled to perform radiofrequency catheter ablation for atrial fibrillation
* Patients who had paroxysmal, persistent, or chronic AF
* Patients provided with the written, informed consent to participate in this study

Exclusion Criteria:

* Patients with prosthetic valve
* Life expectancy \< 12 months
* Subject who the investigator deems inappropriate to participate in this study

Primary outcomes:
measure: Association between mean left atrial pressure and echocardiographic parameters
timeFrame: up to 12 weeks after collecting all data
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine
Study officials:
affiliation: Severance Hospital
name: Jong-Won Ha
role: PRINCIPAL_INVESTIGATOR
References: